Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

autoimmune disease

This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

According to the company, Tavalisse targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing “an important new treatment option for adult patients with chronic ITP”. ... Rigel is also developing it for

Latest news

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    No decision has yet been taken on other autoimmune disease indications for the drug, such as lupus, lupus nephritis, and Sjögren’s syndrome, according to analyst Hur Hye-min of Hi ... Celgene was developing a BTK inhibitor for autoimmune diseases

  • GSK gets another approval for Nucala in US GSK gets another approval for Nucala in US

    The US regulator gave the go-ahead yesterday to use Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, inflammation in ... GSK’s drug is the first to

  • Sanofi licences Principia MS drug in $805m deal Sanofi licences Principia MS drug in $805m deal

    Principa’s lead BTK drug is PRN1008, which is in phase II testing for autoimmune disease pemphigus vulgaris.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Given in combination with methotrexate, the twice-daily administered drug is recommended for adults whose disease hasn’t responded adequately to intensive therapy with conventional or other disease-modifying anti-rheumatic ... According to the National

  • Germany will be first EU launch market for new Soliris indication Germany will be first EU launch market for new Soliris indication

    We are excited about the opportunity to bring Soliris to patients who continue to suffer from this debilitating disease despite current therapies.”. ... While most symptoms in gMG - a chronic and progressive autoimmune disease - can be managed with

More from news
Approximately 3 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to

  • Reaching new heights Reaching new heights

    Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020

  • Pharma deals during May 2014 Pharma deals during May 2014

    Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of

  • The distressing impact of rare diseases The distressing impact of rare diseases

    The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid

  • Pharma deals during February 2013 Pharma deals during February 2013

    During this month, we saw transactions across a range of therapeutic and disease areas (including autoimmune, haematology, metabolic, dermatology) with branded, OTC, generics and biosimilars all represented. ... Autoimmune options. Elan-Biogen's deal was

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Akari Therapeutics strengthens board Akari Therapeutics strengthens board

    His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    and commercialisation of orphan autoimmune and inflammatory disease treatments.

  • Caldan Therapeutics appoints CEO Caldan Therapeutics appoints CEO

    Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Patient Persepective: Autoimmune Disease

    Patient Persepective: Autoimmune Disease. Autoimmune diseases affect 1– 5% of the World’ s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including

  • Random42 Proud To Be Cannes Corporate Award Winners 2016

    Silver Winner - Random 42 for Systematic Lupus Erythematosus. This animation highlights the pathogenesis of Lupus, an autoimmune disease where the body’ s own immune system attacks healthy tissue.

  • Latest wave of Therapy Watch IBD to run this month

    A panel of 200 gastroenterologists will report in 10 IBD patient record forms each quarter (5 Crohn’ s disease and 5 ulcerative colitis), to monitor the evolving IBD treatment landscape.

More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Quick links

Infographics

Multimedia